📄 medicine

Exhaled endogenous pulmonary nitric oxide in intubated and ventilated patients with acute respiratory distress syndrome

This pilot study utilized a prototype Optical Feedback Cavity-Enhanced Absorption Spectroscopy (OFCEAS) analyzer to demonstrate that, contrary to previous indications, fractional exhaled nitric oxide (FeNO) levels do not significantly differ between intubated patients with acute respiratory distress syndrome (ARDS) and control patients, while successfully establishing the feasibility of continuous, cycle-resolved FeNO monitoring in mechanically ventilated individuals.

Original authors: Raphaël Briot, Nicolas Laubriat, Thibault Frappier, Nicolas Favre-Petit-Mermet, Myriam Casez-Brasseur, Florian Sigaud, Marie-Christine Hérault, Géraldine Dessertaine, Marianne Beaumont, Daniele Romani

Published 2026-07-06

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Raphaël Briot, Nicolas Laubriat, Thibault Frappier, Nicolas Favre-Petit-Mermet, Myriam Casez-Brasseur, Florian Sigaud, Marie-Christine Hérault, Géraldine Dessertaine, Marianne Beaumont, Daniele Romanini, Irène Ventrillard

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The Big Picture: Listening to the Lungs' "Whisper"

Imagine your lungs are a busy factory. When the factory is healthy, it runs quietly. But when it gets injured or inflamed (like in a condition called ARDS, which is severe lung swelling), the factory starts making a specific chemical "smoke" called Nitric Oxide (NO).

Doctors have long suspected that if they could measure how much of this "smoke" patients are breathing out, they could tell how bad their lung inflammation is. However, measuring this smoke is incredibly hard because:

It's a whisper: The amount of NO is tiny (parts per billion), like trying to hear a single mosquito buzzing in a hurricane.
The machine is loud: Patients in the ICU are on ventilators (breathing machines) that pump air in and out very fast, making it hard to catch a clear sample.

The Tool: A Super-Sensitive "Gas Microscope"

The researchers built a special device called an OFCEAS analyzer. Think of this as a high-tech gas microscope.

How it works: Instead of just sniffing the air, it uses a laser beam that bounces back and forth inside a tiny tube thousands of times. This makes the light travel a "virtual" distance of several kilometers, allowing it to catch even the faintest trace of Nitric Oxide.
The Advantage: Unlike older machines that are slow or need huge tubes of air (which would mess up the patient's breathing), this device is fast, small, and only takes a tiny sip of air (0.2 liters per minute) so it doesn't disturb the patient's life support.

The Experiment: Two Groups of Patients

The team tested this device on 17 patients in a hospital in Grenoble, France. They split them into two groups:

The "Control" Group: People having routine surgery (like thyroid surgery) who were put to sleep and put on a ventilator, but had healthy lungs.
The "ARDS" Group: People in the ICU with severe, inflamed lungs who were already on ventilators.

The Goal: They wanted to see if the ARDS patients were "smoking" (breathing out) significantly more Nitric Oxide than the healthy surgery patients.

The Problem: The "Blurry Photo" Effect

Here is where the story gets tricky. The ventilators in the ICU were set to breathe very fast (about 20 times a minute). The gas analyzer was fast, but the tubes connecting the patient to the machine were long and had "dead space" (extra volume where air mixes).

Imagine trying to take a photo of a race car going 200 mph with a camera that has a slightly slow shutter speed. The car won't look sharp; it will look like a blur.

The Blur: Because the air was moving so fast through the tubes, the machine couldn't see the sharp "peak" of Nitric Oxide at the end of a breath. It just saw a smooth, blurry wave.
The Raw Data: When they first looked at the blurry waves, the ARDS patients actually looked like they had less NO than the healthy group. This matched some old studies that said inflamed lungs produce less NO.

The Fix: The "CO2 Detective"

The researchers realized they couldn't trust the blurry pictures directly. So, they used a clever trick.

They knew that Carbon Dioxide (CO2) is also in the breath, but it is much easier to see (like a bright red car in the same race). The machine measured CO2 perfectly.

The Analogy: Since the CO2 and NO travel through the same tubes and get blurred by the same "traffic," the researchers used the CO2 signal as a reference map. They calculated a "correction factor" based on how much the CO2 was blurred, and applied that same math to the NO signal to "sharpen" the picture.

The Result: The Plot Twist

Once they applied this math correction to "un-blur" the data, the results changed completely:

Before Correction: It looked like ARDS patients had lower NO.
After Correction: The Nitric Oxide levels in the ARDS patients were almost exactly the same as the healthy surgery patients (around 4.5 to 4.7 parts per billion).

The Conclusion: The study found no significant difference in Nitric Oxide levels between the two groups.

Why Did This Happen? (The Paper's Explanation)

The authors suggest a few reasons why they didn't see a spike in NO, even though the lungs were inflamed:

Timing: They measured the patients within 24 hours of intubation. By this time, the lungs might already be so flooded with fluid (edema) that the "smoke" (NO) produced deep in the lungs can't escape into the air to be measured. It's like trying to smell a candle through a thick wall of water.
Measurement Limits: Even with their fancy laser, the physical tubes and the speed of the ventilator made it impossible to get a perfect, sharp reading.

The Takeaway

This paper is a story about technology meeting reality.

They proved that you can use a laser to monitor these tiny gases in real-time on ventilated patients.
However, they also showed that technical limitations (like tube length and breathing speed) can trick you into seeing the wrong numbers if you don't correct for them.
Finally, they found that in this specific group of very sick patients, the "lung smoke" (NO) wasn't higher than in healthy patients, contradicting some previous ideas that it should be.

In short: The machine works, the math is tricky, and for these specific patients, the lungs weren't "smoking" more than expected, likely because the injury was too deep or the measurement tools were slightly too slow to catch the signal clearly.

Technical Summary: Exhaled Endogenous Pulmonary Nitric Oxide in Intubated and Ventilated Patients with ARDS

Problem Statement
Monitoring endogenous fractional exhaled nitric oxide (FeNO) is a established method for assessing pulmonary inflammation, particularly in asthma. However, its application in mechanically ventilated patients, specifically those with Acute Respiratory Distress Syndrome (ARDS), remains challenging and yields inconsistent results in the literature. Previous studies have reported conflicting conclusions: some suggest FeNO levels are lower in ARDS patients compared to controls, while others indicate higher levels.

A primary technical hurdle is the requirement for analytical devices that possess both sub-parts-per-billion (ppb) sensitivity to detect low NO concentrations and sufficient temporal resolution (sub-second response time) to resolve individual respiratory cycles. Commercial chemiluminescence analyzers, while sensitive, often lack the necessary temporal resolution or require high sampling flows that disrupt clinical ventilation protocols. Furthermore, the high respiratory rates (RR) typical of ARDS patients, combined with the dead volume introduced by medical tubing and filters, can smooth out respiratory cycle amplitudes, leading to potential underestimation of FeNO if not corrected.

Methodology
This study, named ENOBARDS, was a monocentric, observational, non-interventional trial conducted at Grenoble-Alpes University Hospital. It utilized a prototype analyzer based on Optical Feedback Cavity-Enhanced Absorption Spectroscopy (OFCEAS), specifically upgraded for clinical FeNO monitoring.

Instrumentation: The OFCEAS device operates in the mid-infrared range (~5.3 µm), offering a detection limit of 0.3 ppb within 0.2 seconds. It simultaneously measures nitric oxide (NO) and carbon dioxide (CO₂) at a low sampling flow rate of 0.2 L/min, ensuring no disruption to the ventilator circuit.
Study Population: Twenty patients were initially enrolled between January and May 2024. After exclusions due to COPD history, unreliable measurements, or excessively high respiratory rates preventing cycle resolution, the final analysis included 17 patients: 11 controls (undergoing thyroid/parathyroid surgery) and 6 ARDS patients (intubated within 24 hours).
Data Acquisition: Continuous monitoring of NO and CO₂ was performed over 5–10 minutes. The system captured raw concentration data throughout the respiratory cycle.
Data Processing: Due to the high respiratory rates and system dead volume, the raw amplitude of respiratory cycles was often smoothed, preventing direct measurement of end-expiratory plateaus. To address this, the authors developed a correction algorithm. This method utilized the simultaneous CO₂ measurements (which have a high signal-to-noise ratio) to calculate a correction factor ( $\eta$ ). This factor, derived from the CO₂ amplitude and offset, was applied to the raw NO amplitude to estimate the true FeNO values, compensating for the smoothing effects of the gas handling system.

Key Results

Feasibility: The study successfully demonstrated the feasibility of continuous, real-time FeNO monitoring in intubated and mechanically ventilated patients using laser absorption spectroscopy in an intensive care setting.
Raw Data vs. Corrected Data:
- Raw Amplitudes: The uncorrected amplitude of NO respiratory cycles was significantly lower in the ARDS group (median 1.7 ppb) compared to the control group (median 2.8 ppb).
- Corrected FeNO: After applying the CO₂-based correction factor, the difference between the groups disappeared. The median FeNO for ARDS patients was 4.5 ppb [3.6–5.2], and for controls, it was 4.7 ppb [3.2–6.0].
Statistical Outcome: Contrary to initial indications from raw data and some previous literature, the study found no statistically significant difference in FeNO levels between ARDS patients and intubated control patients.
Technical Observations: The correction factor was found to be dependent on the respiratory rate. Higher respiratory rates (common in ARDS) resulted in greater smoothing of the signal and required larger correction factors. The study noted that fully resolving respiratory cycles in intubated patients would require respiratory rates below 4 bpm, which is clinically incompatible with standard care, highlighting the necessity of the correction algorithm.

Significance and Claims
The authors position this work as the first demonstration of continuous FeNO monitoring in intubated and mechanically ventilated patients using laser absorption spectroscopy. The study emphasizes that while the OFCEAS technology offers the necessary sensitivity and speed, the clinical environment introduces specific constraints (tubing dead volume, high RR) that necessitate sophisticated data correction.

The paper modestly concludes that its findings do not support previous reports suggesting elevated NO levels in the exhaled breath of patients with inflammatory lung diseases like ARDS when measured under these specific conditions. Instead, the results suggest that FeNO levels in ARDS patients may not differ significantly from those in intubated controls. The authors attribute the discrepancy with some prior studies to differences in measurement techniques, data analysis methods (specifically the handling of incomplete respiratory cycle resolution), and the timing of measurements relative to the stage of lung injury and edema formation.

The study underscores that accurate FeNO estimation in critical care requires accounting for the physical limitations of the gas sampling system, not just the sensitivity of the detector. It suggests that future investigations should focus on clinical contexts where lower respiratory rates are tolerable (e.g., ex vivo lung perfusion or stable post-surgical patients) to allow for full-resolution cycle monitoring without complex corrections.